Articles by Jan J. Malek - Pharmaceutical Executive


Articles by Jan J. Malek

The New Building Blocks for Blockbusters

Sep 1, 2004

Single drugs for single indications are hard to find. Here's how to get around that.

The Path to Smart R&D

It takes commitment from the top down to optimize portfolio project resource management.
Nov 1, 2003

One of pharma's thorniest challenges is how to optimize the potential value of its R&D portfolio with limited resources. To address that, many pharma and biotech companies have begun to enhance their capabilities in the new discipline of portfolio project resource management (PPRM).

In the Eye of the Storm

Pharma is facing some turbulent years. Companies must prepare now to weather the storm.
Apr 1, 2003

The pharmaceutical industry is experiencing unprecedented late-stage setbacks, product recalls, and difficulties in generating high-quality drug candidates. The problems are not specific to any one company or research effort but rather a result of the industry's limited knowledge of biology and chemistry.

Running a Tight Ship

To be competitive, pharma companies must learn to manage resources more effectively.
Feb 1, 2002

In a tight market, pharma companies are asking themselves: "How can we get more from scarce resources?" As a result, R&D and sales/marketing expenditures are under increased scrutiny-and they should be. Both areas consume significant resources (about 25 percent of revenues combined) have experienced rapid growth, and their results have been difficult to quantify. But to make the most of both human and non-human assets, management must first understand how those assets are currently allocated, how to make them more productive, and if there are better ways to deploy them. That substantial task will be further exacerbated as the industry

Get Ready to Merge or Diverge

In a volatile marketplace, every pharma company must be prepared to keep up with the M&A flow.
Aug 1, 2001

Pharma mergers have hardly brought runaway success. Yet, judging from industry CEOs' public pronouncements, on the horizon is another merger and acquisition wave that will challenge both participants and spectators. The M&A game of the future may diverge drastically from strategies of the past, as multiple acquirers begin to target specific therapeutic franchises rather than whole companies.


Click here